Coherus Biosciences (NASDAQ:CHRS) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.29) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.45) by $0.16, Morningstar.com reports. The firm had revenue of $37.10 million during the quarter, compared to analysts’ expectations of $36.83 million.
Shares of NASDAQ CHRS opened at $17.47 on Friday. The company has a quick ratio of 2.49, a current ratio of 2.54 and a debt-to-equity ratio of 8.29. Coherus Biosciences has a 52 week low of $8.32 and a 52 week high of $20.66. The stock has a market capitalization of $1.12 billion, a P/E ratio of -5.43 and a beta of 3.64.
In related news, CFO Jean-Frederic Viret sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, March 20th. The shares were sold at an average price of $14.92, for a total value of $44,760.00. Following the completion of the sale, the chief financial officer now owns 13,185 shares in the company, valued at $196,720.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 18.20% of the stock is owned by company insiders.
CHRS has been the subject of several recent analyst reports. Robert W. Baird set a $28.00 target price on shares of Coherus Biosciences and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Zacks Investment Research cut shares of Coherus Biosciences from a “hold” rating to a “sell” rating in a research note on Monday, March 25th. ValuEngine cut shares of Coherus Biosciences from a “buy” rating to a “hold” rating in a research note on Saturday, May 4th. BidaskClub upgraded shares of Coherus Biosciences from a “sell” rating to a “hold” rating in a research note on Thursday, January 31st. Finally, Credit Suisse Group set a $25.00 target price on shares of Coherus Biosciences and gave the stock a “buy” rating in a research note on Thursday, March 7th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $28.00.
WARNING: “Coherus Biosciences (CHRS) Posts Quarterly Earnings Results, Beats Expectations By $0.16 EPS” was first published by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://dakotafinancialnews.com/2019/05/11/coherus-biosciences-chrs-posts-quarterly-earnings-results-beats-expectations-by-0-16-eps.html.
About Coherus Biosciences
Coherus BioSciences, Inc, a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body's ability to fight infections. The company sells UDENYCA in the United States.
Featured Article: What is a Call Option?
Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.